NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor

NetraMark adds former Global Atlantic investment office president Kevin Felix as Strategic Advisor to guide capital markets and strategic transaction efforts.

Rhea-AI Summary

NetraMark (AINMF) has appointed veteran global finance executive Kevin Felix as Strategic Advisor to support its commercialization and capital markets strategy.

Felix has more than 25 years of senior leadership experience in capital markets, asset management, corporate strategy and securities law. He most recently served as President of the Investment Office of Global Atlantic Financial Group, overseeing business management and operations for a $175 billion investment portfolio. His prior roles at Scotiabank included President and CEO of Scotia Capital (USA) and Global Head of Fixed Income, Currencies and Commodities. As Strategic Advisor, he will counsel NetraMark on institutional investor and banking relationships, strategic transactions, corporate development and longer-term capital markets strategy in Canada and the United States.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark
  
  

TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Kevin Felix as Strategic Advisor, strengthening the senior strategic and institutional experience surrounding the Company as NetraMark advances its commercialization strategy.

Mr. Felix brings more than 25 years of senior leadership experience across capital markets, asset management, corporate strategy and securities law. Most recently, Mr. Felix served as President of the Investment Office of Global Atlantic Financial Group, responsible for all business management and operational matters related to the firm’s $175 billion investment portfolio. Prior thereto, his senior positions at Scotiabank included President and CEO of Scotia Capital (USA) Inc. and Global Head of Fixed Income, Currencies, and Commodities, a diverse multi-billion dollar business throughout North and South America, Europe and Asia. Mr. Felix also brings extensive corporate governance experience, having served as independent director for several firms.

“Kevin has operated at a high level within the global financial markets,” said George Achilleos, CEO of NetraMark. “As we advance commercialization and broaden the Company’s relationships across the pharmaceutical and investment communities we are continuing to strengthen the level of experience around the organization. Kevin is an exceptional addition.”

“NetraMark has developed a highly differentiated approach to applying artificial intelligence to one of the pharmaceutical industry’s most significant challenges: understanding patient heterogeneity within clinical trials,” said Kevin Felix, Strategic Advisor to NetraMark. “I am excited to work with George and the NetraMark team as they continue building the Company, developing important industry relationships and evaluating the strategic and capital markets opportunities that may accompany its growth.”

Supporting NetraMark’s Next Stage of Growth

As Strategic Advisor, Mr. Felix will advise NetraMark on various matters including Canadian and U.S. institutional investor and investment banking relationships, strategic transactions, corporate development and longer-term capital markets strategy.

Mr. Felix holds a Masters of Law in Securities Regulation from Georgetown University Law Center, a Juris Doctor, cum laude, from New York Law School, and a Bachelor of Arts from Bucknell University.

For more information on NetraMark and NetraAI, visit www.netramark.com.

About NetraAI
NetraAI is engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting," which drowns out critical information that could have been used to improve a trial's chance of success.

About NetraMark
NetraMark is focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions that are targeted at the biotechnology and pharmaceutical industries. The Company's product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets often prevalent in clinical trials, and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential impact and perspective that Kevin Felix can bring to the Company's business and ability to engage with the markets, the Company’s anticipated business plans and strategies, including with respect to commercialization and broadening relationships among pharmaceutical and investment communities and the potential for our technology to extract greater value from clinical trial data and inform subsequent clinical development strategies along with the potential expansion of the application of NetraAI across the pharmaceutical industry, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.com including our Annual Information Form for the year ended September 30, 2025. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
Adam Peeler – Investor Relations | adam.peeler@loderockadvisors.com | 416-427-1235

Media Contact:
netramark@ampublicrelations.com

FAQ

What will Kevin Felix focus on in his role as Strategic Advisor to NetraMark?

As Strategic Advisor, Kevin Felix will advise NetraMark on Canadian and U.S. institutional investor and investment banking relationships, strategic transactions, corporate development and longer-term capital markets strategy.

What relevant experience does Kevin Felix bring to NetraMark?

Kevin Felix has over 25 years of senior leadership experience across capital markets, asset management, corporate strategy and securities law. He previously led Global Atlantic Financial Group’s $175 billion investment office and held senior roles at Scotiabank, including President and CEO of Scotia Capital (USA) and Global Head of Fixed Income, Currencies and Commodities.